ABSTRACT Objectives Previous study (Br. J. Haematol. 2017; 176: 498) reported that CD56
positive is associated with poor prognosis of patients with intermediate-risk acute myeloid …

Acute myeloid leukemia (AML) is a heterogeneous group of disorders with distinct
characteristics and prognoses. Although cytogenetic changes and gene mutations are …

Purpose Extensive studies have investigated the prognostic value of CD56 for patients with
acute myeloid leukemia (AML), but the results remained inconclusive. The aim of this meta …

Background: The aim of this review was to evaluate the influence of aberrant phenotypes in
prognosis and survival in acute myeloid leukemia (AML) patients by multiparametric flow …

BACKGROUND AND OBJECTIVES. CD56 antigen expression has been reported in several
hematologic malignancies. In acute myeloid leukemia (AML) M2 with t (8; 21) and acute …

Abstract CD56 antigen, a 200–220 kDa cell surface glycoprotein, identified as an isoform of
the neural adhesion molecules (NCAM), has been found frequently expressed in several …

BACKGROUND: The expression of CD56 is considered a bad prognostic factor for overall
survival, lower rates or short complete remission and extramedullary invasion but the results …

CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic
phenotype and resistance to induction therapy but no inferior survival after risk-adapted …

A number of clinical and biological factors in acute myeloid leukemia (AML) have been used
to predict the response to induction treatment or the likelihood of relapse …

Flow cytometry‐based immunophenotyping is a mainstay of diagnostics in acute myeloid
leukaemia (AML). Aberrant CD56 and T‐cell antigen expression is observed in a fraction …